Arana in good financial shape despite loss
This article was originally published in Scrip
The Australian antibody company Arana Therapeutics swung to a net loss of A$4.1 million ($2.7 million) for the year to September 30th, despite a healthy rise in revenues.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.